1456534-48-7 Usage
Molecular Weight
269.73 g/mol The mass of one mole of the compound, calculated from its molecular formula.
Appearance
Colorless crystalline solid The physical appearance of the compound, which may be a solid, liquid, or gas at room temperature.
Solubility
Soluble in organic solvents such as ethanol, methanol, and DMSO The solubility of the compound in different solvents, which can affect its handling and use in chemical reactions and applications.
Melting Point
98-102°C The temperature range at which the compound changes from a solid to a liquid state.
Boiling Point
Not available The temperature at which the compound changes from a liquid to a gas state was not provided in the material.
Structure
Pyrimidine ring with a chloro substitution at the 4th position and a phenyl group at the 6th position, attached to an ethyl alcohol group The arrangement of atoms and functional groups in the compound, which determines its chemical properties and potential applications.
Applications
Potential use in medicinal chemistry and drug development, as a building block for the synthesis of novel pharmaceuticals or as a research tool in the study of pyrimidine-based drugs The possible uses of the compound in the field of medicine and pharmaceuticals, based on its structural resemblance to certain bioactive compounds. Further investigation and characterization would be required to confirm its properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1456534-48-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,5,6,5,3 and 4 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1456534-48:
(9*1)+(8*4)+(7*5)+(6*6)+(5*5)+(4*3)+(3*4)+(2*4)+(1*8)=177
177 % 10 = 7
So 1456534-48-7 is a valid CAS Registry Number.
1456534-48-7Relevant academic research and scientific papers
CYCLOLIC HYDRAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
-
Page/Page column 69-70, (2013/09/26)
Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.
